keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant chemoradiotherapy

keyword
https://www.readbyqxmd.com/read/28815077/salvage-esophagectomy-safe-therapeutic-strategy
#1
REVIEW
Sara Jamel, Sheraz R Markar
The objectives of this review were to assess both the short- and long-term clinical outcomes in patients managed with definitive chemoradiotherapy, and salvage esophagectomy subsequently in comparison to those neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS) for esophageal cancer from published literature. Eleven studies comprising 1,906 patients were included, 563 in the salvage group and 1,343 in the NCRS group. Pooled analysis showed no significant difference between salvage and NCRS groups in overall survival [hazard ratio (HR) =1...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28815073/predictive-factors-in-the-evaluation-of-treatment-response-to-neoadjuvant-chemoradiotherapy-in-patients-with-advanced-esophageal-squamous-cell-cancer
#2
REVIEW
Claudia Wong, Simon Law
Neoadjuvant therapy before esophagectomy is evidence-based, and is a standard-of-care for locally advanced and operable esophageal cancer. However response to such treatment varies in individual patients, from no clinical response to pathological complete response. It has been consistently shown that a good pathological responses is of prognostic value, but perhaps in the expense of those who do not. It is important to identify suitable predictive factors for response, so that patients are not exposed to potentially harmful chemotherapy and/or radiotherapy without benefits...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28815065/neoadjuvant-treatment-of-locally-advanced-esophageal-and-junctional-cancer-the-evidence-base-current-key-questions-and-clinical-trials
#3
REVIEW
Claire L Donohoe, John V Reynolds
Recent trials, including CROSS, MAGIC, ACCORD, and OEO2, have established neoadjuvant therapy as standard of care for locally advanced (cT2-3NanyM0) esophageal and junctional cancer compared with surgery alone. The CROSS trial in particular defines a new benchmark for outcomes from multimodal therapy, with a 5 year survival rate of 47%, a median survival of 47 months, a pathologic complete response rate (pCR) of 29% and an R0 resection rate of 92%. Several key questions remain, in particular whether CROSS-regimen chemoradiotherapy is superior to neoadjuvant chemotherapy alone for esophageal cancer, in particular adenocarcinoma...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28807364/initial-results-of-the-oesophageal-and-gastric-cancer-registry-from-the-comunidad-valenciana
#4
Javier Escrig, Fernando Mingol, Roberto Martí, José Puche, Ramón Trullenque, José Antonio Barreras, Francisco Asencio, Javier Aguiló, José Manuel Navarro, Carmen Alberich, Dolores Salas, Francisco Javier Lacueva
AIMS: To evaluate the initial results of the oesophagogastric cancer registry developed for the Sociedad Valenciana de Cirugía and the Health Department of the Comunidad Valenciana (Spain). MATERIAL AND METHODS: Fourteen of the 24 public hospitals belonging to the Comunidad Valenciana participated. All patients with diagnosis of oesophageal or gastric carcinomas operated from January 2013 to December 2014 were evaluated. Demographic, clinical and pathological data were analysed...
August 11, 2017: Cirugía Española
https://www.readbyqxmd.com/read/28807249/current-trends-in-multimodality-treatment-of-esophageal-and-gastroesophageal-junction-cancer-review-article
#5
REVIEW
Fredrik Klevebro, Simon Ekman, Magnus Nilsson
PURPOSE: Multimodality treatment has now been widely introduced in the curatively intended treatment of esophageal and gastroesophageal junction cancer. We aim to give an overview of the scientific evidence for the available treatment strategies and to describe which trends that are currently developing. METHODS: We conducted a review of the scientific evidence for the different curatively intended treatment strategies that are available today. Relevant articles of randomized controlled trials, cohort studies, and meta analyses were included...
September 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28807215/long-term-survival-based-on-pathologic-response-to-neoadjuvant-therapy-in-esophageal-cancer
#6
Gregory Tiesi, Wungki Park, Meredith Gunder, Gustavo Rubio, Michael Berger, Bach Ardalan, Alan Livingstone, Dido Franceschi
BACKGROUND: Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. MATERIALS AND METHODS: A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy...
August 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28803718/total-neoadjuvant-therapy-a-shifting-paradigm-in-locally-advanced-rectal-cancer-management
#7
REVIEW
Aaron J Franke, Hiral Parekh, Jason S Starr, Sanda A Tan, Atif Iqbal, Thomas J George
Colorectal carcinoma is the second leading cause of cancer-related deaths in the United States, with rectal cancer accounting for approximately one-third of newly diagnosed cases, thus representing a major socioeconomic health burden. Although minimally invasive procedures (ie, transanal excision) may be appropriate for a subset of patients with small, superficially invasive tumors, a more comprehensive trimodality approach with neoadjuvant chemoradiotherapy, total mesorectal excision, and systemic chemotherapy is recommended for medically operable patients with nonmetastatic, locally advanced rectal cancer (LARC)...
June 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28801062/perineural-invasion-through-the-sheath-in-posttherapy-esophagectomy-specimens-predicts-poor-survival-in-patients-with-esophageal-squamous-cell-carcinoma
#8
C-Y Tsai, C-J Yeh, Y-K Chao, H-K Chang, C-K Tseng, Y-H Liu
BACKGROUND: The prognostic impact of perineural invasion (PNI) in patients with esophageal cancer who receive neoadjuvant chemoradiotherapy (nCRT) remains unclear. METHODS: A thorough pathological review of PNI was performed on post-nCRT esophagectomy specimens obtained from non-ypT0 patients with esophageal squamous cell carcinoma (ESCC). When PNI was identified, it was classified according to the presence or absence of penetration through the nerve sheath (i.e...
August 3, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28799004/phase-ii-trial-of-laparoscopic-hyperthermic-intraperitoneal-chemoperfusion-for-peritoneal-carcinomatosis-or-positive-peritoneal-cytology-in-patients-with-gastric-adenocarcinoma
#9
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Linus Ho, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
PURPOSE: The aim of this phase II study was to perform neoadjuvant hyperthermic intraperitoneal chemoperfusion (HIPEC) via a minimally invasive approach without cytoreduction for patients with gastric cancer and positive peritoneal cytology or low-volume peritoneal carcinomatosis. METHODS: Patients with gastric or gastroesophageal adenocarcinoma and positive peritoneal cytology or radiologically occult peritoneal carcinomatosis after systemic chemotherapy received laparoscopic HIPEC with mitomycin C 30 mg and cisplatin 200 mg...
August 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28797461/the-importance-of-log-odds-of-positive-lymph-nodes-for-locoregional-recurrence-in-oral-squamous-cell-carcinoma
#10
Ali-Farid Safi, Martin Kauke, Andrea Grandoch, Hans-Joachim Nickenig, Uta Drebber, Joachim Zöller, Matthias Kreppel
OBJECTIVES: Log odds of positive lymph nodes (LODDS) has been demonstrated as a very promising staging model for multiple cancer sites, as it avoids singularity and predicts prognosis significantly better than conventional nodal staging and lymph node ratio. However, published studies on the influence of LODDS for patients with OSCC are very seldom. MATERIAL AND METHODS: Retrospective chart review of 499 patients with treatment-naive oral squamous cell carcinoma...
September 2017: Oral Oncology
https://www.readbyqxmd.com/read/28797063/ct-texture-analysis-in-patients-with-locally-advanced-rectal-cancer-treated-with-neoadjuvant-chemoradiotherapy-a-potential-imaging-biomarker-for-treatment-response-and-prognosis
#11
Choong Guen Chee, Young Hoon Kim, Kyoung Ho Lee, Yoon Jin Lee, Ji Hoon Park, Hye Seung Lee, Soyeon Ahn, Bohyoung Kim
PURPOSE: To evaluate the association of computed tomography (CT) texture features of locally advanced rectal cancer with neoadjuvant chemoradiotherapy (CRT) response and disease-free survival (DFS). METHODS AND FINDINGS: The institutional review board approved this retrospective study. 95 patients who received neoadjuvant CRT, followed by surgery, for locally advanced rectal cancer were included. Texture features (entropy, uniformity, kurtosis, skewness, and standard deviation) were assessed in pretreatment CT images and obtained without filtration and with Laplacian of Gaussian spatial filter of various filter values (1...
2017: PloS One
https://www.readbyqxmd.com/read/28796730/squamous-cancers-of-the-rectum-demonstrate-poorer-survival-and-increased-need-for-salvage-surgery-compared-with-squamous-cancers-of-the-anus
#12
Audrey S Kulaylat, Christopher S Hollenbeak, David B Stewart
BACKGROUND: Squamous cell cancers of the anus are rare GI malignancies for which neoadjuvant chemoradiation is the first-line treatment for nonmetastatic disease. Squamous cancers of the rectum are far less common, and it is unclear to what degree chemoradiotherapy improves their outcomes. OBJECTIVE: The purpose of this study was to compare stage-specific survival for anal and rectal squamous cancers stratified by treatment approach. DESIGN: This was a retrospective cohort study...
September 2017: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/28795280/the-use-of-neoadjuvant-therapy-for-resectable-locally-advanced-thoracic-esophageal-squamous-cell-carcinoma-in-an-analysis-of-5016-patients-from-305-designated-cancer-care-hospitals-in-japan
#13
Yoichiro Tsukada, Takahiro Higashi, Hideaki Shimada, Yoshinori Kikuchi, Atsuro Terahara
BACKGROUND: Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan. METHODS: Data on patients with stage IB-III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013...
August 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28778099/predictive-clinical-model-of-tumor-response-after-chemoradiation-in-rectal-cancer
#14
Marisa D Santos, Cristina Silva, Anabela Rocha, Carlos Nogueira, Fernando Castro-Poças, António Araujo, Eduarda Matos, Carina Pereira, Rui Medeiros, Carlos Lopes
Survival improvement in rectal cancer treated with neoadjuvant chemoradiotherapy (nCRT) is achieved only if pathological response occurs. Mandard tumor regression grade (TRG) proved to be a valid system to measure nCRT response. The ability to predict tumor response before treatment may significantly have impact the selection of patients for nCRT in rectal cancer. The aim is to identify potential predictive pretreatment factors for Mandard response and build a clinical predictive model design. 167 patients with locally advanced rectal cancer were treated with nCRT and curative surgery...
July 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28770295/inclusion-of-pet-ct-into-planning-of-primary-or-neoadjuvant-chemoradiotherapy-of-esophageal-cancer-improves-prognosis
#15
Jan-Christopher Metzger, Daniel Wollschläger, Matthias Miederer, Peter Vaupel, Markus Moehler, Heinz Schmidberger, Arnulf Mayer
BACKGROUND: PET-CT is widely used for both the staging and planning of primary or neoadjuvant chemoradiotherapy for esophageal cancer. Inclusion of PET-CT information into radiotherapy planning often leads to substantial modifications of the target volume. In the case of detection of distant metastases, it may also result in a switch to a palliative treatment approach. This spares patients from therapy-related toxicities that provide no clinical benefit. However, due to a lack of studies, it is currently unclear whether the advantages of PET-CT also translate into a measurable improvement in patient survival...
August 2, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28770104/immunoscore-in-mismatch-repair-proficient-and-deficient-colon-cancer
#16
Erkki-Ville Wirta, Toni Seppälä, Marjukka Friman, Juha Väyrynen, Maarit Ahtiainen, Hannu Kautiainen, Teijo Kuopio, Ilmo Kellokumpu, Jukka-Pekka Mecklin, Jan Böhm
The aim of this study was to investigate immune response and its prognostic significance in colon carcinomas using the previously described Immunoscore (IS). A population-based series of 779 colorectal cancers, operated on between 2000 and 2010, were classified according to tumour, node, metastasis (TNM) status, mismatch repair (MMR), and BRAF mutation status. Rectal cancer cases (n = 203) were excluded as a high proportion of these patients received preoperative neoadjuvant chemoradiotherapy. Tissue microarray (TMA) samples collected from the tumour centre and invasive front were immunostained for CD3 and CD8...
July 2017: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/28768238/preoperative-chemoradiotherapy-for-rectal-cancer-the-sensitizer-role-of-the-association-between-mir-375-and-c-myc
#17
Raquel Conde-Muiño, Carlos Cano, Victoria Sánchez-Martín, Antonio Herrera, Ana Comino, Pedro P Medina, Pablo Palma, Marta Cuadros
Administration of chemoradiation before tumor resection has revolutionized the management of locally advanced rectal cancer, but many patients have proven resistant to this preoperative therapy. Our group recently reported a negative correlation between c-Myc gene expression and this resistance. In the present study, integrated analysis of miRNA and mRNA expression profiles was conducted in 45 pre-treatment rectal tumors in order to analyze the expressions of miRNAs and c-Myc and their relationship with clinicopathological factors and patient survival...
July 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28763327/advanced-age-is-not-a-contraindication-for-treatment-with-curative-intent-in-esophageal-cancer
#18
Francine E M Voncken, Rosa T van der Kaaij, Karolina Sikorska, Erik van Werkhoven, Jolanda M van Dieren, Cecile Grootscholten, Petur Snaebjornsson, Johanna W van Sandick, Berthe M P Aleman
OBJECTIVES: The objective of this study is to compare long-term outcomes between younger and older (70 y and above) esophageal cancer patients treated with curative intent. MATERIALS AND METHODS: Overall survival (OS), disease-free survival (DFS), and locoregional recurrence-free interval were compared between older (70 y and above) and younger (below 70 y) esophageal cancer patients treated between 1998 and 2013. Treatment consisted of neoadjuvant chemoradiotherapy with surgery or definitive chemoradiotherapy: 36 to 50...
July 31, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28756039/muscle-wasting-and-survival-following-pre-operative-chemoradiotherapy-for-locally-advanced-rectal-carcinoma
#19
S Levolger, M G van Vledder, W J Alberda, C Verhoef, R W F de Bruin, J N M IJzermans, J W Burger
BACKGROUND & AIMS: Neoadjuvant chemoradiotherapy (NACRT) has increased local control in locally advanced rectal cancer. Reduced skeletal muscle mass (sarcopenia), or ongoing muscle wasting, is associated with decreased survival in cancer. This study aims to assess the change in body composition during NACRT and its impact on outcome using computed tomography (CT) imaging in locally advanced rectal cancer (LARC) patients. METHODS: LARC patients treated with NACRT were selected from a prospectively maintained database and retrospectively analyzed...
July 13, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28742699/understanding-and-resetting-radiation-sensitivity-in-rectal-cancer
#20
Katherine A Kelley, Rebecca A Ruhl, Shushan R Rana, Elizabeth Dewey, Cristina Espinosa, Charles R Thomas, Robert G Martindale, Sudarshan Anand, Vassiliki L Tsikitis
OBJECTIVE: The aim of the study was to explore specific microRNAs (miRs) in rectal cancer that would predict response to radiation and identify target pathways that may be exploited for neoadjuvant therapies. SUMMARY BACKGROUND DATA: Chemoradiotherapy (CRT) response is a predictor of survival in rectal cancer. Studies have demonstrated changes in RNA expression correlate with chemoradiation sensitivity across cancers. METHODS: Forty-five rectal cancer patients, partial responders (PR = 18), nonresponders (NR = 13), and complete responders (CR = 14) to CRT, as defined by a tumor regression score, were examined...
July 24, 2017: Annals of Surgery
keyword
keyword
31922
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"